Project Grant R21AI194469
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$254K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $506,530 to Albert Einstein College of Medicine and the University of Colorado-Denver to conduct research on the role of cell-to-cell transmission in alphavirus infection and disease. The key objectives are to: Determine the mechanisms by which antibodies block cell-to-cell spread of alphaviruses like chikungunya and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,248,576 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis. The grant, awarded on July 25, 2025, will fund research to understand the cross-protective efficacy of the recently FDA-approved IXCHIQ live attenuated chikungunya virus vaccine against other alphavirus species, assess the vaccine's infectivity and transmissibility in mosquitoes, and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $843,620 to Albert Einstein College of Medicine to develop broadly protective human monoclonal antibody therapies against alphaviruses. The key goals are to: 1) engineer Fc mutations to enhance the in vitro and in vivo properties of broadly neutralizing antibodies, 2) perform viral escape studies to define mechanisms...
The University of Colorado-Denver received a $782,871 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The grant supports research to define mechanisms by which arthritogenic alphaviruses, such as chikungunya and Ross River viruses, evade CD8+ T cell-mediated clearance. The research aims to investigate how type I interferon signaling restricts myeloid cell infection...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $806,693.00 to New York University (NYU) from June 12, 2025 to May 31, 2030. The grant supports research to elucidate the mechanisms governing lymphangiogenesis (growth of lymphatic vessels) in acute and homeostatic inflammation, and to determine the functional consequences of lymphatic encapsulation of B...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $222,708 to The Regents of the University of Colorado, doing business as the University of Colorado-Denver, to elucidate the mechanisms driving the development of chronic Chikungunya virus (CHIKV) arthritis. The funded research aims to: (I) define a viral reservoir in macrophages in joint-associated...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $218,900 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Alabama at Birmingham (UAB) to investigate the molecular determinants that influence flavivirus protease cleavage and how these factors affect viral fitness. The project aims to elucidate the proteolytic mechanisms used by flaviviruses, such as Dengue, Zika, West Nile, and Yellow Fever viruses, to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $530,385.00 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to study how host acetylation factors regulate the activity of the flavivirus NS3 protein, which is essential for viral replication. The research aims to elucidate the molecular mechanisms by which acetylation of NS3 by...
This federal Project Grant award for $246,623.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research at New York University School of Medicine to study the molecular control of tolerogenic dendritic cell function. The research aims to characterize the dendritic cell subset responsible for maintaining T cell tolerance, including investigating aberrant cytokine...
This federal Project Grant award, with ID R21AI187731, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $245,895 award, granted on November 14, 2024, supports research at the Icahn School of Medicine at Mount Sinai to systematically assess the impact of ubiquitination on Flavivirus infection using CRISPR-Cas9 base editing approaches. The goal is to discover novel pathways that promote...